This invention is directed to the three dimensional crystal structure of
Beta-site APP Cleaving Enzyme (BACE), and to the use of this structure in
rational drug design methods to identify agents that may interact with
active sites of BACE. Such agents may represent new therapeutics in the
treatment and/or prevention of Alzheimer's Disease.